About Xoft, a subsidiary of iCAD, Inc.
iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. We work passionately to provide precise, powerful healthcare solutions expertly engineered to optimize operational efficiency, clinician confidence and patient outcomes.
Expand Access to Radiation Therapy
Radiation therapy has been a critical component of cancer treatment for more than 100 years, and more than 1 million cancer patients in the U.S. receive radiation therapy every year. Targeted therapy is now the treatment approach preferred by most oncologists and Xoft's Electronic Brachytherapy (eBx™) is the latest technology to deliver intense therapy directly to cancer sites with minimal exposure to healthy tissues.
As radiation oncologists, physicists, surgeons and healthcare industry professionals, we're all familiar with the research demonstrating that radiation therapy is an essential component of cancer treatment. However, despite its proven ability to help reduce recurrence of cancer and improve survival, many patients do not have access to this critical treatment. In fact, recent studies also show that many patients opt out of receiving radiation therapy due to time, distance or difficulty accessing radiation therapy centers.
This generates two imperatives: improve the delivery of critical therapy and expand patient access. We view our mission at Xoft to expand the volume of patients who can access radiation therapy and dramatically benefit from it and to target cancer more effectively. We see the opportunity for radiation therapy as only partially realized and, with greater access, we can make the technology available to many more radiation oncologists around the globe.
Why Electronic Brachytherapy?
The term brachytherapy means "near therapy," or bringing the source of radiation close to the tissue that is targeted. This is contrasted with external beam, or linear accelerator technology, which delivers treatment from outside the body. Electronic Brachytherapy blends the best of external beam radiation therapy and traditional brachytherapy.
Electronic Brachytherapy eliminates the need for radioactive isotopes and uses an electronic X-ray source to deliver therapy, giving physicians and patients a safer and more easily managed radiotherapy platform that can address a variety of conditions. Through the manipulation of radiation intensity and dose distribution, the proprietary system can be used in many clinical settings. Treatment can be performed without the need for a shielded room, allowing the radiation oncologist and other medical personnel to be present during treatment delivery and minimizing patient anxiety.
We strongly believe that Electronic Brachytherapy has the potential to transform radiation therapy in the same way that linear accelerators did more than a generation ago.
The Axxent® Treatment Platform
From a clinical perspective, Xoft's mission is to target cancer more effectively.
First, rather than focus on a singular radiation treatment device, the company has expended significant R&D and commercialization resources to the development of the Electronic Brachytherapy platform technology.
While Xoft's core technology of a non-radioactive source for radiation medicine is a clear breakthrough, it is the foundation for the creation of the Axxent System of Care, a totally integrated system of care for treating within the body. Research and development efforts to expand the Axxent System of Care are focused on the triangulation of treatment planning, dose delivery and verification of the dose delivered for the creation of dynamic therapy where dose delivery could be modified automatically in real time.
Launching initially with breast and endometrial cancer treatments, the technology easily lends itself for a number of additional cancer indications such as abdominal, spine and brain, to name a few. The Xoft X-ray source has been granted FDA clearance for disorders of the skin — ranging from basal and squamous cell carcinomas.
This recent FDA clearance also covers surface indications, which means that many intraoperative radiation therapy procedures can be performed with the Xoft source — while surgery is being performed. For the patient, this means a one-day surgery combined with treatment. And, again, this gives an opportunity for radiation oncologists to expand the boundaries of care to provide active radiation therapy — with the patient in the operating suite and with clinicians in the room.
Ultimately, Xoft's core technology is X-ray source miniaturization. Placing a small X-ray source in the body, within vessels, surgical cavities and interstitially provides the potential to do everything from providing curative care to more targeted treatment, to one day treatment. Long-term, we think this X-ray technology may also have many applications that are yet to be unveiled.
©2017 Xoft®, a subsidiary of iCAD, Inc. All rights reserved. Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are registered trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.